Developing autologous iPSC-based therapies for Parkinson’s disease treatment

Abi Pinchbeck, Editor, Cell & Gene Therapy Insights, speaks to Kim Raineri, Chief Technology Officer, Aspen Neuroscience, about the development of novel induced pluripotent stem cell (iPSC)-based therapies for Parkinson’s disease. They also discuss the regulatory, safety, and technical challenges in advancing iPSC-based therapies, as well as the company’s goals for future clinical trials.

Please enter your email to access content Read now